NCT00926419 (InjHepAVar) is a Phase 2/Phase 3 clinical trial of Varicella Vaccine in Varicella, sponsored by University of Sao Paulo General Hospital.

Who is sponsoring NCT00926419?

NCT00926419 is sponsored by University of Sao Paulo General Hospital.

What drugs are being tested in NCT00926419?

Interventions in NCT00926419: Varicella Vaccine, Hepatitis A Vaccine.

What condition does NCT00926419 study?

NCT00926419 studies Varicella, Hepatitis A.

Is NCT00926419 still recruiting?

NCT00926419 is currently status unknown. Last updated 22 June 2009.

Last reviewed 2009-06-22 · How we verify

NCT00926419: InjHepAVar

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serological Evaluation of Chickenpox (Varicella) and Hepatitis A Vaccines Using Disposable Needle-Free Syringe Jet Injector (DSJI) Delivery

Status unknown Phase 2/Phase 3 Last updated 22 June 2009

What this trial tests

Phase 2/Phase 3 trial testing Varicella Vaccine in Varicella in 600 participants. Status unknown.

Timeline

1 June 2009

Primary endpoint
1 November 2009

1 May 2010

Quick facts

Lead sponsor	University of Sao Paulo General Hospital
Phase	Phase 2/Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	600
Start date	1 June 2009
Primary completion	1 November 2009
Estimated completion	1 May 2010
Sites	1 location across Brazil

Drugs / interventions tested

Varicella Vaccine — full drug profile →
Hepatitis A Vaccine — full drug profile →

Conditions studied

Varicella — all drugs for Varicella →
Hepatitis A — all drugs for Hepatitis A →

Sponsor

University of Sao Paulo General Hospital

Who can join

Adults 13 Months to 30 Months, any sex, with Varicella or Hepatitis A. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Immunogenicity: General seroconversion rate 45 days following immunization. Safety: General rate of local and systemic adverse events after immunization according to definition established by Brighton Collaboration Group
Time frame: 45 days after immunization

Sponsor's own description

This study aims to assess immunogenicity and safety of nd influence of the delivery system (needle-free injector or syringe with needle) of fractional doses (dose sparing) of two vaccines (Varicella and Hepatitis A vaccines) in children aged 13 to 30 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Varicella Vaccine

Trials testing the same drug.

NCT07473427 — Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Brid · Phase 3 · not yet recruiting
NCT06314724 — Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines · Phase 3 · completed
NCT03375502 — A Study of MG1111 in Healthy Children · Phase 2, PHASE3 · completed
NCT01190228 — Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV · Phase 3 · completed

Other recruiting trials for Varicella

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT05669625 — A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine · Phase 3 · active not recruiting
NCT04471493 — Pediatric and Ambulatory Research in Infectious Diseases · recruiting

Other University of Sao Paulo General Hospital trials

Trials by the same sponsor.

NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07478094 — Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost · not yet recruiting
NCT07341386 — Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07242092 — Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs · Phase 4 · not yet recruiting
NCT07484152 — Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00926419 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo General Hospital
Last refreshed: 22 June 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00926419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing